151257-06-6 Usage
General Description
1,3-Diazaspiro[4.4]non-1-ene,2-butyl-(9CI) is a chemical compound with a complex and specific chemical structure. It is also known as 2-butyl-1,3-diazaspiro[4.4]non-1-ene. 1,3-Diazaspiro[4.4]non-1-ene,2-butyl-(9CI) is a spirocyclic heterocyclic compound, meaning it contains both a spiro and a heterocyclic ring. It is primarily used in the field of organic chemistry as a building block or intermediate for the synthesis of other chemical compounds. Its unique structure and properties make it suitable for various chemical reactions and transformations, making it a valuable component for the production of pharmaceuticals, agrochemicals, and other fine chemicals. Due to its specific nature, 1,3-Diazaspiro[4.4]non-1-ene,2-butyl-(9CI) is not commonly encountered outside of laboratory settings or research and development activities in the chemical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 151257-06-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,1,2,5 and 7 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 151257-06:
(8*1)+(7*5)+(6*1)+(5*2)+(4*5)+(3*7)+(2*0)+(1*6)=106
106 % 10 = 6
So 151257-06-6 is a valid CAS Registry Number.
151257-06-6Relevant articles and documents
A New Series of Imidazolones: Highly Specific and Potent Nonpeptide AT1 Angiotensin II Receptor Antagonists
Bernhart, Claude A.,Perreaut, Pierre M.,Ferrari, Bernard P.,Muneaux, Yvette A.,Assens, Jean-Louis A.,et al.
, p. 3371 - 3380 (1993)
Starting from the structure of the novel nonpeptide AT1 receptor antagonists DuP 753 (losartan), a new series of potent antagonists was designed.In these compounds the central imidazole nucleus was replaced by the dihydroimidazol-4-one structure.The most active compounds had a spirocyclopentane or a spirocyclohexane ring in position 5.Like the imidazole series, the best substituents were the linear butyl chain in position 2 and the methyl group in position 3.Antagonistic activity was assessed by the ability of the compounds to competively inhibit AII binding to the AT1 subtype receptor and to antagonize AII-induced contractions in rabbit aorta rings.The most active compounds had IC50 values in the nanomolar range.In conscious rats, compounds 4 and 21 antagonized the AII pressor response when administered orally.Compound 21 (SR 47436) was the most active; it was recently shown to also be active in cynomolgus monkeys both intravenously and orally.This molecule is now undergoing clinical trials for the treatment of hypertension.
